Literature DB >> 12658269

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.

S Brian Wilson1, Terry L Delovitch.   

Abstract

Invariant CD1D-restricted natural killer T (iNKT) cells function during innate and adaptive immunity and regulate numerous immune responses, such as autoimmune disease, tumour surveillance, infectious disease and abortions. However, the molecular basis of their functions and the nature of disease-associated defects of iNKT cells are unclear and have been the subject of recent controversy. Here, we review recent findings that underscore the potential importance of interactions between iNKT cells and dendritic cells (DCs) that indicate that iNKT cells regulate DC activity to shape both pro-inflammatory and tolerogenic immune responses. The ability to modulate iNKT-cell activity in vivo using the ligand alpha-galactosylceramide and to treat patients with autoimmune disease or cancer is evaluated also.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658269     DOI: 10.1038/nri1028

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  80 in total

1.  Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type.

Authors:  Y-G Chen; S-W Tsaih; D V Serreze
Journal:  Genes Immun       Date:  2011-09-22       Impact factor: 2.676

Review 2.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  Regulation of immune responses by CD1d-restricted natural killer T cells.

Authors:  Luc Van Kaer
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 5.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

6.  Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.

Authors:  Isabel Sada-Ovalle; Markus Sköld; Tian Tian; Gurdyal S Besra; Samuel M Behar
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

7.  Commitment toward the natural T (iNKT) cell lineage occurs at the CD4+8+ stage of thymic ontogeny.

Authors:  Jelena S Bezbradica; Timothy Hill; Aleksandar K Stanic; Luc Van Kaer; Sebastian Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

8.  Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice.

Authors:  Yi-Guang Chen; John P Driver; Pablo A Silveira; David V Serreze
Journal:  Immunogenetics       Date:  2007-07-10       Impact factor: 2.846

Review 9.  Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis.

Authors:  Joanne Turner; Jordi B Torrelles
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

10.  An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.

Authors:  D Ly; R Tohn; B Rubin; H Blumenfeld; G S Besra; N Veerapen; S A Porcelli; T L Delovitch
Journal:  Clin Exp Immunol       Date:  2009-12-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.